These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 32665269)

  • 1. SERINC5 Potently Restricts Retrovirus Infection
    Timilsina U; Umthong S; Lynch B; Stablewski A; Stavrou S
    mBio; 2020 Jul; 11(4):. PubMed ID: 32665269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent Enhancement of HIV-1 Replication by Nef in the Absence of SERINC3 and SERINC5.
    Wu Y; Olety B; Weiss ER; Popova E; Yamanaka H; Göttlinger H
    mBio; 2019 Jun; 10(3):. PubMed ID: 31186327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional Interplay Between Murine Leukemia Virus Glycogag, Serinc5, and Surface Glycoprotein Governs Virus Entry, with Opposite Effects on Gammaretroviral and Ebolavirus Glycoproteins.
    Ahi YS; Zhang S; Thappeta Y; Denman A; Feizpour A; Gummuluru S; Reinhard B; Muriaux D; Fivash MJ; Rein A
    mBio; 2016 Nov; 7(6):. PubMed ID: 27879338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SERINC3 and SERINC5 restrict HIV-1 infectivity and are counteracted by Nef.
    Usami Y; Wu Y; Göttlinger HG
    Nature; 2015 Oct; 526(7572):218-23. PubMed ID: 26416733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of Different Glycoproteins and of the Virion Core on SERINC5 Antiviral Activity.
    Diehl WE; Guney MH; Vanzo T; Kyawe PP; White JM; Pizzato M; Luban J
    Viruses; 2021 Jun; 13(7):. PubMed ID: 34209034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Murine Leukemia Virus Glycosylated Gag Reduces Murine SERINC5 Protein Expression at Steady-State Levels via the Endosome/Lysosome Pathway to Counteract SERINC5 Antiretroviral Activity.
    Li S; Ahmad I; Shi J; Wang B; Yu C; Zhang L; Zheng YH
    J Virol; 2019 Jan; 93(2):. PubMed ID: 30355687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The antiviral activity of rodent and lagomorph SERINC3 and SERINC5 is counteracted by known viral antagonists.
    de Sousa-Pereira P; Abrantes J; Bauernfried S; Pierini V; Esteves PJ; Keppler OT; Pizzato M; Hornung V; Fackler OT; Baldauf HM
    J Gen Virol; 2019 Feb; 100(2):278-288. PubMed ID: 30566072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. S2 from equine infectious anemia virus is an infectivity factor which counteracts the retroviral inhibitors SERINC5 and SERINC3.
    Chande A; Cuccurullo EC; Rosa A; Ziglio S; Carpenter S; Pizzato M
    Proc Natl Acad Sci U S A; 2016 Nov; 113(46):13197-13202. PubMed ID: 27803322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Murine Leukemia Virus P50 Protein Counteracts APOBEC3 by Blocking Its Packaging.
    Zhao W; Akkawi C; Mougel M; Ross SR
    J Virol; 2020 Aug; 94(18):. PubMed ID: 32641479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Full-Length Glycosylated Gag of Murine Leukemia Virus Can Associate with the Viral Envelope as a Type I Integral Membrane Protein.
    Renner TM; Bélanger K; Lam C; Gerpe MCR; McBane JE; Langlois MA
    J Virol; 2018 Mar; 92(6):. PubMed ID: 29298890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aromatic Side Chain at Position 412 of SERINC5 Exerts Restriction Activity toward HIV-1 and Other Retroviruses.
    Tan TS; Toyoda M; Tokunaga K; Ueno T
    J Virol; 2021 Aug; 95(18):e0063421. PubMed ID: 34190600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Conserved Acidic-Cluster Motif in SERINC5 Confers Partial Resistance to Antagonism by HIV-1 Nef.
    Stoneham CA; Ramirez PW; Singh R; Suarez M; Debray A; Lim C; Jia X; Xiong Y; Guatelli J
    J Virol; 2020 Mar; 94(7):. PubMed ID: 31941773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AP-2 Adaptor Complex-Dependent Enhancement of HIV-1 Replication by Nef in the Absence of the Nef/AP-2 Targets SERINC5 and CD4.
    Olety B; Usami Y; Wu Y; Peters P; Göttlinger H
    mBio; 2023 Feb; 14(1):e0338222. PubMed ID: 36622146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Evolutionary Histories of Antiretroviral Proteins SERINC3 and SERINC5 Do Not Support an Evolutionary Arms Race in Primates.
    Murrell B; Vollbrecht T; Guatelli J; Wertheim JO
    J Virol; 2016 Sep; 90(18):8085-9. PubMed ID: 27356902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IFITM3 Reduces Retroviral Envelope Abundance and Function and Is Counteracted by glycoGag.
    Ahi YS; Yimer D; Shi G; Majdoul S; Rahman K; Rein A; Compton AA
    mBio; 2020 Jan; 11(1):. PubMed ID: 31964738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nef Obtained from Individuals with HIV-1 Vary in Their Ability to Antagonize SERINC3- and SERINC5-Mediated HIV-1 Restriction.
    Kruize Z; van Nuenen AC; van Wijk SW; Girigorie AF; van Dort KA; Booiman T; Kootstra NA
    Viruses; 2021 Mar; 13(3):. PubMed ID: 33800773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Emerging Role of the Serine Incorporator Protein Family in Regulating Viral Infection.
    Xu S; Zheng Z; Pathak JL; Cheng H; Zhou Z; Chen Y; Wu Q; Wang L; Zeng M; Wu L
    Front Cell Dev Biol; 2022; 10():856468. PubMed ID: 35433679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Antagonism of HIV-1 Nef to SERINC5 Particle Infectivity Restriction Involves the Counteraction of Virion-Associated Pools of the Restriction Factor.
    Trautz B; Pierini V; Wombacher R; Stolp B; Chase AJ; Pizzato M; Fackler OT
    J Virol; 2016 Dec; 90(23):10915-10927. PubMed ID: 27681140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of SERINC5-001 as the Predominant Spliced Isoform for HIV-1 Restriction.
    Zhang X; Zhou T; Yang J; Lin Y; Shi J; Zhang X; Frabutt DA; Zeng X; Li S; Venta PJ; Zheng YH
    J Virol; 2017 May; 91(10):. PubMed ID: 28275190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An N-Glycosylated Form of SERINC5 Is Specifically Incorporated into HIV-1 Virions.
    Sharma S; Lewinski MK; Guatelli J
    J Virol; 2018 Nov; 92(22):. PubMed ID: 30158294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.